Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3-L1 cells

BioFactors

Volumn 36, Issue 6, 2010, Pages 459-467

  Lee, Ok Hwan ^a   Seo, Dong Ho ^b   Park, Cheon Seok ^b   Kim, Young Cheul ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CATALASE; FATTY ACID BINDING PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 4; GLUTATHIONE REDUCTASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PUERARIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CELL DIFFERENTIATION; CELL LINE; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLUCOSEPHOSPHATE DEHYDROGENASE; INSULIN; ISOFLAVONES; MICE; OXIDATION-REDUCTION; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASODILATOR AGENTS;

PUERARIA MONTANA VAR. LOBATA;

EID: 78650098818     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.119     Document Type: Article

References (59)

1. Olefsky, J. M., Ciaraldi, T. P., and Kolterman, O. G. ( 1985) Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am. J. Med. 79, 12-22.
2. Olefsky, J. M. and Nolan, J. J. ( 1995) Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am. J. Clin. Nutr. 61, 980S-986S.
3. Lebovitz, H. E. ( 2001) Insulin resistance: definition and consequences. Exp. Clin. Endocrinol. Diabetes 109, S135-S148.
4. Zimmet, P., Alberti, K. G., and Shaw, J. ( 2001) Global and societal implications of the diabetes epidemic. Nature 414, 782-787.
5. Ruan, H. and Lodish, H. F. ( 2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 14, 447-455.
6. Guilherme, A., Virbasius, J. V., Puri, V., and Czech, M. P. ( 2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 367-377.
7. Després, J. P. and Lemieux, I. ( 2006) Abdominal obesity and metabolic syndrome. Nature 444, 881-887.
8. Greenberg, A. S. and McDaniel, M. L. ( 2002) Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur. J. Clin. Invest. 3, 24-34.
9. Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y., Tanaka, S., Tataranni, P. A., Knowler, W. C., and Krakoff, J. ( 2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57-58.
10. Lindsay, R. S., Funahashi, T., Krakoff, J., Matsuzawa, Y., Tanaka, S., Kobes, S., Bennett, P. H., Tataranni, P. A., Knowler, W. C., and Hanson, R. L. ( 2003) Genome-wide linkage analysis of serum adiponectin in the Pima Indian population. Diabetes 52, 2419-2425.
11. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T., and Matsuzawa, Y. ( 1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83.
12. Hotta, K., Funahashi, T., Bodkin, N. L., Ortmeyer, H. K., Arita, Y., Hansen, B. C., and Matsuzawa, Y. ( 2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50, 1126-1133.
13. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. ( 2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946.
14. Heilbronn, L., Smith, S. R., and Ravussin, E. ( 2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 4, S12-S21.
15. Yang, X., Jansson, P. A., Nagaev, I., Jack, M. M., Carvalho, E., Sunnerhagen, K. S., Cam, M. C., Cushman, S. W., and Smith, U. ( 2004) Evidence of impaired adipogenesis in insulin resistance. Biochem. Biophys. Res. Commun. 317, 1045-1051.
16. MacDougald, O. A. and Mandrup, S. ( 2002) Adipogenesis: forces that tip the scales. Trends Endocrinol. Metab. 13, 5-11.
17. Reginato, M. J. and Lazar, M. A. ( 1999) Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol. Metab. 10, 9-13.
18. Arner, P. ( 2003) The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14, 137-145.
19. Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., and Reitman, M. L. ( 2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228.
20. Nadler, S. T., Stoehr, J. P., Schueler, K. L., Tanimoto, G., Yandell, B. S., and Attie, A. D. ( 2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA 97, 11371-11376.
21. Jansson, P. A., Pellme, F., Hammarstedt, A., Sandqvist, M., Brekke, H., Caidahl, K., Forsberg, M., Volkmann, R., Carvalho, E., Funahashi, T., Matsuzawa, Y., Wiklund, O., Yang, X., Taskinen, M. R., and Smith, U. ( 2003) A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 17, 1434-1440.
22. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., and Shimomura, I. ( 2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752-1761.
23. Houstis, N., Rogen, E. D., and Lander, E. S. ( 2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948.
24. Okuno, Y., Matsuda, M., Kobayashi, H., Morita, K., Suzuki, E., Fukuhara, A., Komuro, R., Shimabukuro, M., and Shimomura, I. ( 2008) Adipose expression of catalase is regulated via a novel remote PPARgamma-responsive region. Biochem. Biophys. Res. Commun. 366, 698-704.
25. Feskens, E. J., Virtanen, S. M., Räsänen, L., Tuomilehto, J., Stengård, J., Pekkanen, J., Nissinen, A., and Kromhout, D. ( 1995) Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the finnish and dutch cohorts of the seven countries study. Diabetes Care 18, 1104-1112.
26. Venn, B. J. and Mann, J. I. ( 2004) Cereal grains, legumes and diabetes. Eur. J. Clin. Nutr. 2058, 1443-1461.
27. Melby, M. K., Murashima, M., and Watanabe S. ( 2004) Phytochemical intake and relationship to past health history in Japanese women. Biofactors 22, 265-269.
28. Hermansen, K., Sondergaard, M., Hoie, L., Carstensen, M., and Brock, B. ( 2001) Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24, 228-233.
29. Anderson, J. W., Johnstone, B. M., and Cook-Newell, M. E. ( 1995) Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333, 276-282.
30. Hsu, F. L., Liu, I. M., Kuo, D. H., Chen, W. C., Su, H. C., and Cheng, J. T. ( 2003) Antihyperlycemic effect of puerarin in streptozotocin-induced diabetic rats. J. Nat. Prod. 66, 788-792.
31. Meezan, E., Meezan, E. M., Jones, K., Moore, R., Barnes, S., and Prasain, J. K. ( 2005) Contrasting effects of puerarin and daidzein on glucose homeostasis in mice. J. Agric. Food Chem. 53, 8760-8767.
32. Xu, M. E., Xiao, S. Z., Sun, Y. H., Zheng, X. X., Ou-Yang, Y., and Guan, C. ( 2005) The study of anti-metabolic syndrome effect of puerarin in vitro. Life Sci. 77, 3183-3196.
33. Xu, X. H. ( 2003) Effects of puerarin on fatty superoxide in aged mice induced by D-galactose. Chin. J. Chin. Mater. Med. 28, 66-69.
34. Zhu, Q. L., He, A. X., and Lu, X. R. ( 2001) Effects of puerarin on the scavenge of oxygen free radicals and the antagonism against oxidative injury. Pharm. J. Clin. PLA 17, 1-4.
35. Student, A. K., Hsu, R. Y., and Lane, M. D. ( 1980) Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. J. Biol. Chem. 225, 4745-4750.
36. Blumberg, J. M., Tzameli, I., Astapova, I., Lam, F. S., Flier, J. S., and Hollenberg, A. N. ( 2006) Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J. Biol. Chem. 28, 11205-11213.
37. Bradford, M. ( 1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
38. Deutsch, J. ( 1983) Glucose-6-phosphate dehydrogenase. In Methods of Enzymatic Analysis, ( Bergmeyer, H. U. and Bergmeyer, J. eds.), 3rd edn. pp. 191-197, Verlag Chemie, Berlin.
39. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. ( 1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ. J. Biol. Chem. 270, 12953-12956.
40. Prasain, J. K., Jones, K., Brissie, N., Moore, R., Wyss, J. M., and Barnes, S. ( 2004) Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry. J. Agric. Food Chem. 52, 3708-3712.
41. Cho, K. W., Lee, O. H., Banz, W. J., Moustaid-Moussa, N., Shay, N. F., and Kim, Y. C. ( 2009) Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARgamma transcriptional activity. J. Nutr. Biochem., DOI:10.1016/j.jnutbio.2009.06.012.
42. Kletzien, R. F., Clarke, S. D., and Ulrich, R. G. ( 1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41, 393-398.
43. Wu, Z., Xie, Y., Morrison, R. F., Bucher, N. L., and Farmer, S. R. ( 1998) PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101, 22-32.
44. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., and Matsuzawa, Y. ( 2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099.
45. Ahima, R. S. ( 2006) Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity 14, 9S-15S.
46. Sowers, J. R. ( 2008) Endocrine functions of adipose tissue: focus on adiponectin. Clin. Cornerstone 9, 32-38.
47. Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., Komuro, R., Ouchi, N., Kihara, S., Tochino, Y., Okutomi, K., Horie, M., Takeda, S., Aoyama, T., Funahashi, T., and Matsuzawa, Y. ( 2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8, 731-737.
48. Kadowaki, T. and Yamauchi, T. ( 2005) Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439-451.
49. Nawrocki, A. R., Rajala, M. W., Tomas, E., Pajvani, U. B., Saha, A. K., Trumbauer, M. E., Pang, Z., Chen, A. S., Ruderman, N. B., Chen, H., Rossetti, L., and Scherer, P. E. ( 2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor-γ agonists. J. Biol. Chem. 281, 2654-2660.
50. Kubota, N., Terauchi, Y., Kubota, T., Kumagai, H., Itoh, S., Satoh, H., Yano, W., Ogata, H., Tokuyama, K., Takamoto, I., Mineyama, T., Ishikawa, M., Moroi, M., Sugi, K., Yamauchi, T., Ueki, K., Tobe, K., Noda, T., Nagai, R., and Kadowaki, T. ( 2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281, 8748-8755.
51. Spiegelman, B. M. ( 1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514.
52. Staels, B. and Fruchart, J. C. ( 2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54, 2460-2470.
53. Wellen, K. E. and Hotamisligil, G. S. ( 2005) Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119.
54. Rudich, A., Tirosh, A., Potashnik, R., Hemi, R., Kanety, H., and Bashan, N. ( 1998) Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47, 1562-1569.
55. Sun, X. H., Ding, J. P., Li, H., Pan, N., Gan, L., Yang, X. L., and Xu, H. B. ( 2007) Activation of large-conductance calcium-activated potassium channels by puerarin: the underlying mechanism of puerarin-mediated vasodilation. J. Pharmacol. Exp. Ther. 323, 391-397.
56. Deng, X. G., Hu, S. X., Zhang, Q. J., Yang, J. N., Lin, S. C., and Chen, K. ( 2004) Pharmacokinetic study of puerarin in retinal tissue of rabbits by intraperitoneal injection. Zhong Cao Yao 35, 1382-1384.
57. Wu, Y. H., Su, Z., Lai, X. P., Yao, H., and Lin, J. ( 2004) Studies on pharmacokinetics and bioavailability of puerarin in Yufeng Ningxin tablet in mice. Zhongyao Xinyao Linchuang Yaoli 15, 259-261.
58. Jin, X. L., Cheng, G. F., and Zhu, X. Y. ( 1991) Pharmacokinetics of puerarin in healthy volunteers. Zhongguo Linchuang Yaolixue Zazhi 7, 115-118.
59. Ma, Z., Wu, Q., Lee, D. Y., Tracy, M., and Lukas, S. E. ( 2005) Determination of puerarin in human plasma by high performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 823, 108-114.